Bleomycin A6
- Generic Name
- Bleomycin A6
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C60H96N20O21S2
- CAS Number
- 37293-17-7
- Unique Ingredient Identifier
- 0B19OCB220
- Background
Bleomycin A6 (also known as boanmycin) has been used in trials studying the treatment of Squamous Cell Lung Cancer. It was developed in China as an antineoplastic antibiotic. This drug participated in clinical trials for the treatment of Squamous Cell Lung Cancer. It was shown that besides the antitumor effect, Bleomycin A6 had the ability to alter the tumor microenvironment and could contribute toward lung cancer relapse and metastasis on long-term treatment. The development of this drug, apparently, was discontinued.
- Associated Conditions
- -
- Associated Therapies
- -
Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT01660399
- Locations
- 🇨🇳
Department of Pulmonary Medical Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.